Abstract
G protein-coupled receptors (GPCRs) are major drug targets and are organized in dimeric/oligomeric complexes. These dimers may be composed of identical (homodimer) or different (heterodimer) receptors. GPCR dimerization provides new opportunities for drug design. Different strategies have been developed to specifically target GPCR dimers. Bivalent ligands, which are composed of two functional pharmacophores linked by a spacer, are among the most promising strategies. Due to the constitutive nature of GPCR dimers, bivalent ligands are expected in most cases to bind to and stabilize preexisting dimers rather then to promote ligand-induced dimerization. Most studies on GPCR dimerization were conducted so far in heterologous expression systems. Due the development of heterodimerspecific tools such as bivalent ligands, dimerization has now been confirmed for an increasing number of receptors in native tissues. In this review, we will discuss general considerations for the design and synthesis of bivalent ligands and present the functional in vitro and in vivo properties of reported bivalent ligands.
Keywords: Bivalent ligand, GPCR dimerization, drug design, spacer attachment point, spacer size, spacer chemical structure, heterodimers, GPCR oligomers
Current Drug Discovery Technologies
Title: Bivalent Ligands as Specific Pharmacological Tools for G Protein-Coupled Receptor Dimers
Volume: 5 Issue: 4
Author(s): Isabelle Berque-Bestel, Frank Lezoualc'h and Ralf Jockers
Affiliation:
Keywords: Bivalent ligand, GPCR dimerization, drug design, spacer attachment point, spacer size, spacer chemical structure, heterodimers, GPCR oligomers
Abstract: G protein-coupled receptors (GPCRs) are major drug targets and are organized in dimeric/oligomeric complexes. These dimers may be composed of identical (homodimer) or different (heterodimer) receptors. GPCR dimerization provides new opportunities for drug design. Different strategies have been developed to specifically target GPCR dimers. Bivalent ligands, which are composed of two functional pharmacophores linked by a spacer, are among the most promising strategies. Due to the constitutive nature of GPCR dimers, bivalent ligands are expected in most cases to bind to and stabilize preexisting dimers rather then to promote ligand-induced dimerization. Most studies on GPCR dimerization were conducted so far in heterologous expression systems. Due the development of heterodimerspecific tools such as bivalent ligands, dimerization has now been confirmed for an increasing number of receptors in native tissues. In this review, we will discuss general considerations for the design and synthesis of bivalent ligands and present the functional in vitro and in vivo properties of reported bivalent ligands.
Export Options
About this article
Cite this article as:
Berque-Bestel Isabelle, Lezoualc'h Frank and Jockers Ralf, Bivalent Ligands as Specific Pharmacological Tools for G Protein-Coupled Receptor Dimers, Current Drug Discovery Technologies 2008; 5 (4) . https://dx.doi.org/10.2174/157016308786733591
DOI https://dx.doi.org/10.2174/157016308786733591 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Anti-Diabetic Effects of Isolated Lipids from Natural Sources through Modulation of Angiogenesis
Current Molecular Pharmacology Diabetes and Chronic Heart Failure: From Diabetic Cardiomyopathy to Therapeutic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Barriers to Risk Stratification Accuracy in Ischemic Heart Disease in Women: The Role of Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Isoflurane Preconditioning Protects the Myocardium Against Ischemia and Reperfusion Injury by Upregulating GRM1 Expression
Current Neurovascular Research Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation
Current Pharmaceutical Design The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia
Current Neurovascular Research Conduction Disorders in the Setting of Acute STEMI
Current Cardiology Reviews Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design The Role of Platelets and their Microparticles in Rehabilitation of Ischemic Brain Tissue
CNS & Neurological Disorders - Drug Targets Biological Active Ingredients of Traditional Chinese Herb Astragalus membranaceus on Treatment of Diabetes: A Systematic Review
Mini-Reviews in Medicinal Chemistry Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Angiotensin Converting Enzyme 2 Activator (DIZE) Modulates Metabolic Profiles in Mice, Decreasing Lipogenesis
Protein & Peptide Letters The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design